RT Journal Article
SR Electronic
T1 Neonatal-onset autoinflammation and immunodeficiency caused by heterozygous missense mutation of the proteasome subunit β-type 9
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.01.21250077
DO 10.1101/2021.02.01.21250077
A1 Kanazawa, Nobuo
A1 Hemmi, Hiroaki
A1 Kinjo, Noriko
A1 Ohnishi, Hidenori
A1 Hamazaki, Jun
A1 Mishima, Hiroyuki
A1 Kinoshita, Akira
A1 Mizushima, Tsunehiro
A1 Hamada, Satoru
A1 Hamada, Kazuya
A1 Kawamoto, Norio
A1 Kadowaki, Saori
A1 Honda, Yoshitaka
A1 Izawa, Kazushi
A1 Nishikomori, Ryuta
A1 Tsumura, Miyuki
A1 Yamashita, Yusuke
A1 Tamura, Shinobu
A1 Orimo, Takashi
A1 Ozasa, Toshiya
A1 Kato, Takashi
A1 Sasaki, Izumi
A1 Fukuda-Ohta, Yuri
A1 Wakaki-Nishiyama, Naoko
A1 Inaba, Yutaka
A1 Kunimoto, Kayo
A1 Okada, Satoshi
A1 Taketani, Takeshi
A1 Nakanishi, Koichi
A1 Murata, Shigeo
A1 Yoshiura, Koh-ichiro
A1 Kaisho, Tsuneyasu
YR 2021
UL http://medrxiv.org/content/early/2021/02/02/2021.02.01.21250077.abstract
AB BACKGROUND Defective proteasome activities due to genetic mutations lead to an autoinflammatory disease, termed as proteasome-associated autoinflammatory syndromes (PRAAS). In PRAAS relapsing inflammations and progressive wasting are common, but immunodeficiency has not been reported.METHODS We studied two unrelated Japanese infants with PRAAS-like manifestations. We have also generated and analyzed the mice carrying the candidate mutation found in the patients.RESULTS Both patients showed neonatal-onset skin rash, myositis and basal ganglia calcification, similar to PRAAS patients. Meanwhile, they manifested distinct phenotypes, including pulmonary hypertension and immunodeficiency without lipoatrophy. We identified a novel de novo heterozygous missense mutation, G156D, in a proteasome subunit gene, PSMB9, encoding β1i, in the two patients. Maturation and activity of the immunoproteasome were impaired, but ubiquitin accumulation was hardly detected not only in patient-derived cells and samples but also in Psmb9G156D/+ mice. As an immunodeficient phenotype, one patient showed decrease of B cells and increase of monocytes, while the other patient showed decrease of CD8 T cells. The proteasome defects and immunodeficient phenotypes were recapitulated in Psmb9G156D/+ mice.CONCLUSIONS The PSMB9 G156D is a unique mutation in proteasome subunits in causing defects by its heterozygosity, affecting two β rings interaction and leading to immunodeficiency. The mutant mice are the first mice model for analyzing proteasome dysfunctions in PRAAS. We here propose the term, proteasome-associated autoinflammation and immunodeficiency disease (PRAID), as an umbrella name for our cases, PRAAS with immunodeficiency, as well as PRAAS described so far.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by Health Labor Sciences Research Grants for Research on Intractable Diseases (grant 20316700 and 20317089 to H. Ohnishi) from the Ministry of Health, Labour and Welfare (MHLW) of Japan; by the Practical Research Project for Rare/Intractable Diseases under Grant Numbers JP15gk0110012 (to K. Yoshiura), JP16ek0109179 and JP19ek0109209 (to S. Okada), JP17ek0109100 (to N. Kanazawa), JP19ek0109199 (to, N. Kanazawa, H. Hemmi, N. Kinjo K. Yoshiura, and T. Kaisho), JP20ek0109480 (to H. Ohnishi and S. Okada), and Advanced Research and Development Programs for Medical Innovation (AMED-CREST) under Grant Number JP20gm1110003 (to S. Murata) from the Japan Agency for Medical Research and Development (AMED); by Grants-in-Aids for Scientific Research (A) (grant JP18H04022 to S. Murata), Scientific Research (B) (grant 16H05355 and JP19H03620 to S. Okada, grant JP17H04088 and JP20H03505 to T. Kaisho), for Scientific Research (C) (grant JP15K09780 and JP19K08798 to N. Kanazawa, grant JP18K07840 to H. Ohnishi, grant JP19K07628 to I. Sasaki, grant JP18K07071 to H. Hemmi, grant JP16K10171 and JP19K08754 to K. Kunimoto), for Young Scientists (grant JP19K17293 to K. Izawa, grant JP20K16289 to T. Orimo, JP18K16096 to Y. Fukuda-Ohta), for Scientific Research on Innovative Areas (grant JP17H05799 and JP19H04813 to T. Kaisho, JP18H05500 to S. Murata), for Exploratory Research (grant JP17K19568 to T. Kaisho), for Young Scientists (B) (grant JP16K19585 to Y. Fukuda-Ohta), Research Activity start-up (grant JP19K23848 to T. Orimo), Promotion of Joint International Research from the Japan Society for the Promotion of Science (JP18KK0228 to S. Okada) from the Japan Society for the Promotion of Science; by the Uehara Memorial Foundation (to I. Sasaki and T. Kaisho); by Takeda Science Foundation (to H. Hemmi, T. Mizushima, I. Sasaki and T. Kaisho); by the Ichiro Kanehara Foundation for the promotion of Medical Sciences and Medical care (to H. Hemmi); by the Inamori Foundation (to I. Sasaki); by the Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University; by a Cooperative Research Grant from the Institute for Enzyme Research, Joint Usage/Research Center, Tokushima University; by the Grant for Joint Research Program of the Institute for Genetic Medicine Hokkaido University; by the Grant for Joint Research Project of the Institute of Medical Science, the University of Tokyo; by the Program of the Network type Joint Usage/Research Center for Radiation Disaster Medical Science; by Wakayama Medical University Special Grant-in-Aid for Research Projects.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the University of the Ryukyus for Medical and Health Research Involving Human Subjects, the Ethics Boards of Gifu University, the Ethics Committee on Human Genome / Gene Analysis Research of Nagasaki University, the Research Ethics Committee and the Animal Research Committee of Wakayama Medical University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnyone who wishes to share, reuse, remix, or adapt this material must obtain permission from the corresponding authors.